RESUMO
In Europe, several national networks have been established to undertake clinical research of medicines for children. In the Netherlands, the Dutch Medicines for Children Research Network (MCRN) was launched in September 2008. The purpose of the Dutch MCRN is to improve the speed, quality, and coordination of clinical drug research in children, ultimately resulting in better patient care.
Assuntos
Pesquisa Biomédica/organização & administração , Ensaios Clínicos como Assunto/normas , Desenvolvimento de Programas , Criança , Humanos , Países Baixos , Avaliação de Programas e Projetos de SaúdeRESUMO
In a randomized, controlled trial, 105 healthy full-term infants born to HBsAg and HBeAg positive mothers received three doses (at 0, 1 and 6 months) of either a new recombinant hepatitis B vaccine (Hepavax-Gene) or Engerix-B. Both groups were also given hepatitis B specific Hepa-big immunoglobulin (HBIG) within 24h of birth. Levels of antibodies to hepatitis B surface antigen (anti-HBs) were assessed on days 30, 60, 210, 360, and 2 years post-vaccination. Efficacy and immunogenicity and safety of the two vaccines were not significantly different; both vaccines achieved >94% seroprotection within 360 days. At 2 years, only one subject (1.9%) in the Hepavax-Gene group and two subjects (3.9%) in the Engerix-B group were HBsAg positive. No serious adverse events (AEs) were observed in either group.